Lipid Disorders
From the Journals
Meta-analysis throws more shade aspirin’s way
A large meta-analysis raises more questions about the benefit of low-dose aspirin in people who don’t have atherosclerotic cardiovascular disease...
From the Journals
Exercise training reduces liver fat in patients with NAFLD, even without weight loss
“Prior to our study, it was felt that body weight loss of at least 5% was required in order to significantly improve liver histology. Our findings...
Commentary
Keto for life? Reasons to think twice
Is the Keto diet best for weight loss? Maybe in the short term, but it’s more complicated than that. Dr. Caroline Apovian explains why.
From the Journals
Persistent gaps in drug use by patients with type 2 diabetes
Continuous use of glucose-, BP-, and cholesterol-lowering medications by adults with mainly type 2 diabetes declined in 2005-2019. This may...
Commentary
‘Ozempic face’: Accepting wrinkles for improved health
Some who are taking Ozempic are complaining about their faces thinning as an effect of this weight-loss drug. Dr. Anne Peters thinks the benefit...
Commentary
Universal testing for Lp(a): What are we waiting for?
A resurgent interest in molecular pathophysiology this past decade has clarified Lp(a)’s unique contribution to atherothrombotic disease and...
From the Journals
CV deaths jumped in 2020, reflecting pandemic toll
The American Heart Association 2020 Statistical Update offers lessons for addressing structural issues that drive health disparities.
From the Journals
High HDL-C levels linked to increased fracture risk
High levels of high-density lipoprotein cholesterol are associated with a higher risk for fracture among older adults, a cohort study suggests.
From the Journals
PCSK9 inhibitors for severe COVID? Pilot trial signals of benefit
“PCSK9 inhibition may represent a novel therapeutic pathway in addition to currently recommended therapeutic approaches for severe COVID-19.”
From the Journals
Size of meals, not timing, linked to weight loss
More small meals were associated with weight loss, regardless of time between them, in a prospective cohort study.
From the Journals
Evolocumab’s LDL lowering surpassed inclisiran’s in ORION-3
Results from a crossover subgroup of 92 patients in ORION-3 documented evolocumab’s greater LDL-lowering efficacy, compared with inclisiran.